The biggest potential concern about GLP-1 microdosing is that a person may not be taking enough of a medication to treat the condition for which it has been prescribed
Maloney A, Rosenstock J, Fonseca V
Health Canadas target timeline for the first review of generic drug submissions is 180 days, which the agency says is shorter than similar international regulators
In 2024, a multi-society clinical practice guideline was issued jointly by the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the American Society of Anesthesiologists (ASA), the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons [112]
Food and supplement companies could develop product lines specifically formulated for GLP-1 usershigh-protein, nutrient-dense options in smaller portions that align with reduced appetite and altered taste preferences